Status:
WITHDRAWN
Multislice Computed Tomography Assessment of PCSK9 Inhibition on Coronary Perfusion
Lead Sponsor:
ECRI bv
Collaborating Sponsors:
Amgen
GE Healthcare
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The MARKOV study is an investigator-sponsored single arm, prospective study to assess the effect of evolocumab on the improvement in coronary flow (FFRCT) after 18 and 36 months of treatment in patien...
Detailed Description
The MARKOV study is an investigator-initiated, open-label, single arm, international, multicenter, prospective study to assess the effect of evolocumab on the improvement in coronary flow (FFRCT) afte...
Eligibility Criteria
Inclusion
- At least 2 coronary vessels suitable for CCTA; vessels fulfilling all requirements below: a. patent main branch b. no previous stent placement
- At least two of the evaluable vessels with subclinical coronary artery disease as defined non-invasively by CCTA with encroachment of the vessel and either: a. Lesion with visual diameter stenosis (DS) \< 50% or, b. Lesion with visual DS ≥ 50% and FFRCT \> 0.80;
- No planned coronary revascularization (during the course of the study) at the time of enrollment;
- Most recent, taken within 30 days prior to informed consent form (ICF) signature, fasting LDL-C ≥ 80 mg/dL (≥ 2.07 mmol/L) and on stable statin therapy for at least 30 days at the time of blood sampling, or statin-intolerant or for whom a statin is contraindicated.
- Subject signed informed consent form
Exclusion
- History of coronary artery bypass surgery, heart transplantation, surgical or percutaneous valve repair and/or replacement
- New York Heart Association (NYHA) class III or IV heart failure
- Last known left ventricular ejection fraction \<30%
- Active liver disease or hepatic dysfunction, either known or defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3 times the upper limit of normal (ULN)
- Severe renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m2
- Active malignancy except for adequately treated non-melanoma skin cancer or other non-invasive or in situ neoplasm (e.g. successfully treated cervical cancer in situ or non-active prostate cancer) Imaging CCTA-related
- Absence of baseline CCTA obtained in the context of standard clinical care
- Baseline CCTA not meeting Core Lab quality standards
- Any contraindication for repeat CCTA such as known anaphylactic allergy to iodinated contrast
- Concomitant and study medication
- Any prior or current use of PCSK9 inhibition treatment or any other experimental lipid-related drug Other exclusion criteria
- LDL or plasma apheresis within 12 months of screening
- Subject \< 18 years of age
- Legally incompetent to provide written informed consent;
- Known pregnancy or breast-feeding at time of screening
- Female subject of childbearing potential, i.e. who are not surgically sterile or post-menopausal (defined as no menses for 2 years without an alternative cause)
- Male subject with female partner of childbearing potential who is not using highly effective birth control
- Currently participating in another trial
Key Trial Info
Start Date :
August 30 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 24 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03851263
Start Date
August 30 2019
End Date
February 24 2023
Last Update
December 6 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.